Pulse Biosciences, Inc

PLSE Healthcare Medical Instruments & Supplies

Pulse Biosciences, Inc’s revenue for fiscal 2025 (year ended December 2025) was $350,000.00, down 50.0% from fiscal 2022.

Revenue
+359.3%
EPS
−10.3%
Free cash flow
−1,180.5%

Quarter to September 2026, against a year earlier

53.38 0.31 +0.58%
Market cap
$3.9B
P/E
0.0×
Fwd P/E
−38.1×
Dividend yield
—
F-score
n/a
Altman Z
31.41
Beneish M
n/a
Dividend safety
n/a

Pulse Biosciences, Inc (PLSE) EV/FCF

Alert me on EV/FCF

As of 5 November 2026, Pulse Biosciences, Inc (PLSE) trades at a EV/FCF of −17.8×. Over the past ten years it has ranged from −61.6× (September 2026) to −0.6× (August 2022); the current reading is higher than 32% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2025 −16.7× —
FY2022 −2.1× —
FY2021 −7.3× —

Quarterly newest first

Period EV/FCF Change
Sep 2026 −16.8× —
Jun 2026 −30.7× —
Mar 2026 −26.4× —
Dec 2025 −16.7× —
6 more quarters

Against its own ten years

Low −61.6× High −0.6×
Ten-year median −11.5×
Current reading's percentile 32

EV/FCF against peers

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on PLSE